Manipulating Metabolism: Lilly Links With UK Biotech Sitryx

Pair Will Act On Intracellular Metabolic Pathways To Modify Diseases

Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.

Wooden_Blocks_Metabolism
Pact aims to regulate cell metabolism and generate novel medicines • Source: Shutterstock

The development of new medicines for autoimmune diseases has brought Sitryx Therapeutics and Eli Lilly & Co. together in an exclusive research and licensing collaboration where the young British biotech will be responsible for drug discovery while the US pharma giant will foot the bill and eventually get commercial rights to the resulting therapies.

The five-year collaboration, announced on 31 March, will study up to four novel preclinical targets identified by Sitryx that could...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip